How User-Centered Perspectives Foster Innovation in Digital Health Surveillance for Epidemic Intelligence in Europe

By Charmi Patel

May 27, 2024

Introduction

Epidemic intelligence (EI) is crucial for managing public health threats. Effective data reporting and surveillance systems are essential for timely responses. However, various challenges hinder these processes. This article highlights the challenges faced by EI practitioners and suggests improvements.

The COVID-19 pandemic has underscored the importance of robust EI systems. The rapid spread of the virus highlighted gaps in data collection, reporting, and analysis. These gaps can delay responses and exacerbate public health crises. As we move forward, it is vital to address these challenges to better prepare for future health emergencies.

Challenges in Data Reporting

Data reporting is a complex task, especially when dealing with large datasets. For instance, the European Centre for Disease Prevention and Control (ECDC) requires datasets to be split into parts with no more than 500 records. This requirement complicates the process, especially for countries like Italy, which have thousands of records. Frequent changes in data entry formats further exacerbate the issue, leading to coordination costs and reduced data reliability.

Moreover, the transparency of data from outside the European Union requires careful validation. This lack of confidence in data reliability can hinder effective decision-making.

Figure 2: Process for initial user needs assessment and prioritization implemented by the MOOD consortium in 2020. WP: Work groups of the consortium
Figure 2: Process for initial user needs assessment and prioritization implemented by the MOOD consortium in 2020. WP: Work groups of the consortium

Strategic Objectives and Resource Allocation

Different countries have varying priorities for infectious disease surveillance. For example, France focuses on Aedes-borne diseases due to the changing distribution of mosquito vectors. In contrast, Italy prioritises West Nile Virus (WNV) monitoring due to its impact on blood deferral and vector control.

Resource allocation also varies, affecting the quality of surveillance. Limited resources and poor integration between stakeholders can impede the implementation of a One Health plan for antimicrobial resistance (AMR). The lack of cost benefit analysis for vector control strategies further complicates resource allocation.

Professional Networks and Collaboration

EI practitioners emphasise the importance of professional networks for data validation and strategy review. Strengthening these networks can improve data collection and sharing. However, multisectoral collaborations face challenges due to differing priorities and structural constraints.

For instance, the integration of human and animal health sectors is often limited by a lack of understanding of intersectoral relations. This gap hinders the development of comprehensive surveillance plans.

Proposed Improvements

To address these challenges, several improvements are suggested. First, enhancing the interoperability of information technology (IT) systems can streamline data reporting. Standardising data entry formats and interfaces can reduce coordination costs and improve data reliability.

Second, increasing resource allocation for surveillance activities is crucial. Conducting cost benefit analyses can help optimise resource use and improve the quality of surveillance.

Third, fostering professional networks and collaborations can enhance data validation and strategy development. Regular exchanges of experiences and procedures between countries can lead to better surveillance practices.

Finally, adopting a prospective approach to surveillance can help address new threats more quickly. This approach involves anticipating future challenges and preparing accordingly.

Conclusion

Effective EI systems can significantly impact healthcare resource allocation, ensuring that interventions are both cost-effective and timely. By improving data reporting and surveillance, we can better understand the economic burden of diseases and allocate resources more efficiently.

Moreover, robust EI systems can facilitate market access for new healthcare solutions by providing comprehensive data on disease prevalence and treatment outcomes. This data is crucial for demonstrating the value of new interventions to payers and policymakers. Robust surveillance can also support dynamic pricing strategies, allowing for more flexible and responsive pricing models based on real-time data.

In conclusion, investing in improved EI systems will yield substantial benefits in terms of both public health and economic efficiency. By addressing the current challenges in data reporting and surveillance, we can enhance our ability to respond to health threats, optimise resource allocation, and support the market access of innovative healthcare solutions.

Reference url

Recent Posts

lenacapavir HIV PrEP access
    

Global Health Partnerships Unite to Expand Access to Lenacapavir for HIV Prevention

💉 How can we ensure equitable access to HIV prevention methods like lenacapavir?

A recent initiative from the Global Fund, supported by key global health organizations, aims to provide affordable access to this new HIV pre-exposure prophylaxis medication.

With a goal to reach 2 million individuals over three years, this coordinated effort seeks to drastically cut HIV infections and align with our commitment to ending AIDS by 2030.

Explore the details of this impactful collaboration and how it could transform HIV prevention.

#SyenzaNews #globalhealth #HealthcareInnovation #MarketAccess

antimicrobial resistance africa
     

Africa’s Health Crisis: Antimicrobial Resistance and Mpox Outbreak

🌍 Are we prepared to tackle the hidden pandemic of antimicrobial resistance (AMR) in Africa?

With AMR rapidly becoming a dominant health crisis, it’s critical to understand its impact on our healthcare systems and most vulnerable populations.

The Africa CDC highlights the urgent need for substantial investment and coordinated responses to combat this escalating threat, alongside the ongoing Mpox outbreak.

Discover the pressing challenges and potential solutions in our latest article.

#SyenzaNews #GlobalHealth #HealthcareInnovation #AntimicrobialResistance #PublicHealth

BioSapien cancer drug delivery
    

BioSapien Innovative Cancer Drug Delivery Solutions

🌟 How is innovation in drug delivery shaping the future of cancer treatment? 🌟

Discover how UAE-based BioSapien is transforming the healthcare landscape with the MediChip™ platform, securing $5.5 million in pre-Series A funding to enhance cancer care.

This innovative solution promises to minimise side effects and improve treatment outcomes for patients, fully embracing the potential of biotechnology in the fight against cancer.

Read more about BioSapien’s journey and its impact on global health!

#SyenzaNews #biotechnology #oncology #innovation #HealthTech

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.